Superantigens stimulate T-cell-receptor V␤-selective T-cell proliferation accompanying the release of cytokines, which may eventually protect the host from microbial infections. We investigated here whether superantigens can rescue the host from lethal bacterial infection. Mice were pretreated with Staphylococcus aureus enterotoxin B (SEB) 1 and 2 days before bacterial infection, and the mortality of infected mice was assessed. SEB pretreatment protected mice from lethal infection with Listeria monocytogenes but not from lethal infection with Streptococcus pyogenes. This enhanced protection was also observed upon pretreatment with recombinant streptococcal pyrogenic exotoxin A. Furthermore, L. monocytogenes-specific delayed-type hypersensitivity (DTH) due to type 1 helper T (Th1) cells and the cytotoxicity of CD8 ؉ T cells were significantly enhanced after SEB administration and bacterial infection. Depletion of either CD4 ؉ T cells or CD8 ؉ T cells in SEBpretreated mice completely abolished this protection. This phenomenon was ascribed to the elimination of L. monocytogenes-specific CD8 ؉ cytotoxic T lymphocytes (CTL). It was found that CD4 ؉ T cells contributed to the induction of the CTL populations. Furthermore, SEB pretreatment of heat-killed L. monocytogenesimmunized mice enhanced the protection from challenge of L. monocytogenes. Taken together, these results indicated that administrations of superantigens protected mice from infection with L. monocytogenes, which was dependent on the enhanced L. monocytogenes-specific CTL activity in the presence of CD4 ؉ T cells, and superantigens exhibited adjuvant activity in the immunization against intracellular pathogens.
Staphylococcus aureus and Streptococcus pyogenes are known to produce 20-to 30-kDa exotoxins, e.g., staphylococcal enterotoxin B (SEB) and streptococcal pyrogenic exotoxin A (SPEA). These toxins cause lethal toxic shock in humans and animals (3, 15, 18, 24) . They elicit a variety of pathophysiological activities and activate T cells in a T-cell-receptor (TCR) V␤-specific manner. They also bind directly to major histocompatibility complex (MHC) class II molecules and activate T cells bearing one or few types of the variable region of ␤ chain (V␤) of the TCR, causing the release of cytokines. By this mechanism, these exotoxins stimulate 5 to 30% of T cells (3, 24) and are termed superantigens (54) .
Listeria monocytogenes is a gram-positive and facultative intracellular bacterium that causes meningitis, sepsis, and abortions (19) . The virulence factor of L. monocytogenes is listeriolysin O (LLO), which destroys the phagocytic vacuoles, allowing endocytosed organisms to be released into the cytoplasm of their target cells, where they proliferate. Protection against L. monocytogenes infection is mediated by innate and adaptive immunologic mechanisms (46) . Neutrophils (7), macrophages, natural killer (NK) cells (10) , and ␥␦-T cells (16) are responsible for the innate immunity in the early phase of infection, while adaptive immunity against L. monocytogenes depends on ␣␤-T cells. Among these immune cells, class I MHCrestricted CD8 ϩ cytotoxic T lymphocytes (CTLs) found in the spleen, liver, and peritoneum seem to play critical roles in conferring protective immunity. The LLO and murein hydrolase p60 protein secreted from L. monocytogenes are targets for the CD8
ϩ CTLs, and LLO-or p60-specific CD8 ϩ CTL clones mediate protective immunity against L. monocytogenes in vivo (13, 38, 39) .
After stimulation of T cells with superantigens, various kinds of cytokines such as gamma interferon (IFN-␥), tumor necrosis factor alpha (TNF-␣), granulocyte-monocyte colony-stimulating factor, interleukin-1 (IL-1), IL-2, IL-6, IL-8, and IL-12 are secreted (6, 28) . Exceeding secretion of TNF-␣ in a host may result in lethal toxic shock (31, 32) . However, moderate secretion of cytokines such as IFN-␥, TNF-␣, and IL-1 is necessary to induce innate immune responses for protection of host from bacterial infection (6, 34) . Furthermore, superantigen exposure significantly enhanced the T-cell-dependent host response to bacterial antigens in the in vitro coculture system (30) . In this regard, Nichterlein et al. (37) reported that pretreatment with SEB increased the clearance of L. monocytogenes, which suggests that pretreatment of the host with low levels of superantigens may help to protect against bacterial infections. However, it is not yet known whether pretreatment of host with low levels of superantigens could protect against lethal L. monocytogenes infection.
In this study, we investigated whether the administration of superantigens offered protection from lethal bacterial infections and, if so, which type of host defense mechanism was responsible.
MATERIALS AND METHODS
Bacteria, mice, and cell lines. L. monocytogenes EGD was provided by M. Mitsuyama (Kyoto University, Kyoto, Japan). S. pyogenes SSI-1 (M3) was an isolate from a Japanese patient with severe invasive fasciitis and was provided by T. Murai (Toho University, Tokyo, Japan). L. monocytogenes was grown over-night in brain heart infusion (BHI) broth (Difco Laboratories, Detroit, Mich.) at 37°C. S. pyogenes was grown for 6 h in Todd-Hewitt broth supplemented with 0.2% yeast extract (Difco Laboratories) at 37°C. After being washed with sterile phosphate-buffered saline (PBS), bacterial cells were resuspended in PBS for a mortality test in mice. Female BALB/c mice (H-2 d , 6 to 10 weeks old) were purchased from Clea Japan, Inc. (Osaka, Japan). The 50% lethal doses (LD 50 s) of L. monocytogenes and S. pyogenes in mice were found to be 10 4 CFU and 4 ϫ 10 4 CFU, respectively. Mouse macrophage cell line J774A.1 (H-2 d ) (42) and mastocytoma cell line P815 (H-2 d ) (40) were cultured in RPMI 1640 medium (Gibco-BRL, Grand Island, N.Y.) containing 10% fetal calf serum, L-glutamine, ␤-mercaptoethanol, penicillin G (100 U/ml), streptomycin (100 g/ml), and gentamicin (50 g/ml).
MAbs, toxins, and peptides. Monoclonal antibodies (MAbs) to CD3ε, CD4, and CD8 were prepared from hybridoma cell lines 145-2C11 (27), GK1.5 (55), and 2.43 (45) , respectively. These hybridoma cells were injected intraperitoneally (i.p.) into BALB/c nu/nu mice (Charles River Japan, Tokyo, Japan), and MAbs were purified from the ascites fluids by using MabTrap GII (Amersham Pharmacia Biotech, Uppsala, Sweden). Purified rabbit antibody to asialoganglioside GM1 (AsGM1) was purchased from Wako Pure Chemicals (Osaka, Japan). Control rat immunoglobulin G (IgG) and fluorescein isothiocyanate (FITC)-or phycoerythrin (PE)-conjugated MAbs were purchased from PharMingen (San Diego, Calif.). SEB was purchased from Sigma (St. Louis, Mo.). Recombinant SPEA (rSPEA) was obtained according to the method of Fagin et al. (11 (38) , respectively, were custom-made by Sawady Technology (Tokyo, Japan). These peptides were dissolved in PBS at a concentration of 1 mg/ml and stored at Ϫ20°C until use.
Bacterial infection, pretreatment with superantigens, and depletion of NK or T-cell subsets in vivo. To examine mortality after infection with test organisms, mice were given 10 6 Cytokine assay. Sera were collected by centrifugation at 1,000 ϫ g at 4°C for 15 min, and the samples were stored at Ϫ70°C until use. Cytokine assays were performed by enzyme-linked immunosorbent assay (ELISA) with a Cytoscreen ELISA KIT (Bio Source International, Camarillo, Calif.).
Phagocytic assay of macrophage to L. monocytogenes. Spleen cells (10 8 cells) from mice were suspended in 10 ml of complete RPMI 1640 medium containing 20% fetal calf serum and then poured into a plastic petri dish (10 cm in diameter; Becton Dickinson) and incubated in a humidified incubator at 37°C for 2 h in air with 5% CO 2 . After incubation, adherent macrophages were harvested, and 5 ϫ 10 6 cells were suspended in 1 ml of RPMI 1640 medium. L. monocytogenes (5 ϫ 10 6 CFU) were suspended in 1 ml of RPMI 1640 medium containing 20% normal mouse serum and incubated for 10 min at 37°C, and the macrophage suspensions (1 ml) and L. monocytogenes suspensions (1 ml) were then mixed. The mixtures and L. monocytogenes suspensions were rotated at 37°C for 2 h in a humidified incubator in air with 5% CO 2 . The mixtures (100 l) and L. monocytogenes suspension (50 l) were plated on BHI agar plates, and colonies were counted after incubation overnight at 37°C. The percent clearance of L. monocytogenes is presented as 100% ϫ (CFU in 50 l of L. monocytogenes suspension Ϫ CFU in 100 l of the mixture)/(CFU in 50 l of L. monocytogenes suspension).
DTH. Delayed-type hypersensitivity (DTH) was assessed as described by Tsukada et al. (50) with some modifications. Forty mice were divided into four groups (10 mice per group): I to IV. The group I mice were not treated. Mice in groups III and IV were infected i.v. with 10 4 CFU of L. monocytogenes. Mice in groups II and IV were treated i.p. with SEB (10 g) twice. All mouse spleens were harvested 7 days after infection, and T cells were separated and purified using a nylon wool column (20) The peptide pulsed target P815 cells (100 l) were added to 96-well flat-bottom microtiter plates (Becton Dickinson) at 10 4 cells/well and were used as target cells. Effector T cells in a 100-l volume were added at an effector/target ratio of 30 to 1. The cytotoxicity was assayed, and the percent specific lysis was determined as described above.
ELISPOT assay. Enzyme-linked immunospot (ELISPOT) assay was performed to assess the number of IFN-␥-producing cells in the spleen of L. monocytogenes-infected mice as described by Vijh and Pamer (52) . (Fig. 1) . Pretreatment of mice with SEB (10 g/mouse) protected them from infection with L. monocytogenes at up to 3 ϫ 10 6 CFU (ϭ 300 ϫ LD 50 ) (data not shown). However, treatment of mice with SEB 1 and 2 days after infection with 10 6 CFU of L. monocytogenes organisms did not show any protection compared to nontreated mice (data not shown). It was also shown that a recombinant streptococcal superantigen, rSPEA, protected all mice from lethal infection with L. monocytogenes but not from lethal infection with S. pyogenes (Fig. 1) .
Effect of the secretion of cytokines after pretreatment with SEB. Since various kinds of cytokines such as IFN-␥ and TNF-␣ are secreted in SEB-treated mice (28), we compared the secretion between SEB-pretreated mice and nontreated mice. Figure 2 shows that secretion of IFN-␥ and TNF-␣ in SEB-primed mice increased temporarily. Furthermore, after infection with L. monocytogenes, the secretion of IFN-␥ and TNF-␣ in the sera and spleens of SEB-pretreated mice was diminished promptly. This result indicates that the enhanced host defense was not due to the enhanced cytokine secretions.
Effect of innate immunity after pretreatment with SEB. We determined which type of immune response, innate immunity or adaptive immunity, was enhanced in this situation. The influence of innate immunity by pretreatment with SEB was assessed by phagocytosis of spleen macrophages to L. monocytogenes. In Fig. 3 , macrophages in SEB-pretreated mice were less phagocytic than those in nonpretreated mice, suggesting that innate immunity does not function after pretreatment with SEB.
Effect of adaptive immunity after pretreatment with SEB. We next assessed whether pretreatment of mice with SEB could enhance the Listeria-specific T-cell response, which consisted of a Th cell response and a CTL response, in vivo. To determine the influence of Th cell activity by pretreatment with SEB, mice in groups C and D had their footpads infected with HKL and spleen T cells from only L. monocytogenes-infected mice or from SEB-pretreated and L. monocytogenes-infected mice, and the DTH response of the two groups was compared. As shown in Fig. 4 , the DTH response of mice injected with HKL and spleen T cells from SEB-pretreated and L. monocytogenes-infected mice was significantly higher than that of mice injected with HKL and spleen T cells of only L. monocytogenesinfected mice. On the other hand, a DTH response of mice injected with HKL and spleen T cells from mice that were only SEB pretreated was not detected (Fig. 4) .
Cytotoxicity of the effector T cells was then examined against L. monocytogenes-infected J774A.1 cells, as described in Materials and Methods. Pretreatment of mice with SEB resulted in significantly enhanced cytotoxicity (Fig. 5A) , which was abolished by depletion of CD8 ϩ T cells (Fig. 5B) , indicating that cytotoxicity of CD8 ϩ CTL is enhanced by pretreatment with SEB. Listeria-specific CD8 ϩ CTLs recognize the peptides of LLO on MHC class I molecules of L. monocytogenes-infected cells (37, 38) . Thus, we determined whether the increased cytotoxicity of CD8 ϩ CTLs was really specific for Listeria to assess the cytotocity for Listeria peptide-labeled target cells. The results presented in Fig. 6A show that the cytotoxicity for LLO (91-99)-or p60 (217-225)-labeled P815 cells was significantly enhanced by the SEB. To determine whether the enhanced cytotoxicity was due to the increased number of Listeria-specific CD8 ϩ CTLs, an ELISPOT assay was performed as described in Materials and Methods. The number of IFN-␥-producing cells, i.e., Listeria-specific CD8 ϩ CTLs, was dramatically increased by SEB (Fig. 6B) .
Protection of SEB-pretreated mice from L. monocytogenes infection by depletion of T cells. Since L. monocytogenes-specific T-cell responses, but not the innate immune response, were enhanced by SEB pretreatment of mice, we examined whether T cells were necessary to protect SEB-treated mice from lethal L. monocytogenes. T or NK cells from SEB-treated mice were depleted by systemic administration of MAb specific for CD3 or antibody specific for AsGM1. T-or NK-cell-depleted mice were infected, and mortality was assessed. We found that anti-AsGM1 antibody-treated or control anti-rat IgG-treated mice were all survived, whereas all of the anti-CD3 MAb-treated mice were killed within 3 days after the infection (Fig. 7) .
Role of CD4 ؉ and CD8 ؉ T cells in the protection from lethal L. monocytogenes infection due to CTL. The results presented above raised the question as to which type of T cells elicited the enhanced protection of mice from lethal L. monocytogenes infection after the SEB treatment. To answer this, the mortality of SEB-pretreated and T-cell-subset-depleted mice was assessed. Depletion of CD4 ϩ T cells or CD8 ϩ T cells in SEB-pretreated mice diminished protection from the lethal L. monocytogenes infection (Fig. 8A) . However, depletion of 
CD8
ϩ T cells in SEB-pretreated mice did not affect the L. monocytogenes-specific DTH (Fig. 8B) . Furthermore, we found that the depletion of CD4 ϩ T cells, as well as of CD8 ϩ T cells, abolished CTL activity against L. monocytogenes-infected J774A.1 cells (Fig. 8C) . These results indicated that CD8 ϩ CTLs of SEB-pretreated mice are critically important effector cells for the protection, whereas CD4 ϩ T cells sustained this CTL activity.
Protection against L. monocytogenes challenge in HKL-immunized mice and effect of SEB. Pretreatment of mice with SEB before immunization with Listeria proteins might enhance the protection against L. monocytogenes challenge. Mice were injected twice with PBS or SEB, 1 and 2 days before infection, and then immunized s.c. with HKL (5 ϫ 10 7 CFU), CFA (100 l), or HKL plus CFA twice. These mice were then infected with 10 4 CFU of L. monocytogenes organisms/mouse 35 days after the secondary immunization, and the number of L. monocytogenes in the spleen was determined. The numbers of L. monocytogenes in the spleen of mice given SEB and HKL were 10 times less than in mice given SEB, CFA, or HKL (Fig. 9) . We also found that the number of L. monocytogenes in mice given SEB and HKL was significantly lower than in the spleen of mice given CFA and HKL (Fig. 9) , indicating that SEB exhibited more effective adjuvant activities than CFA for immunization with HKL.
DISCUSSION
We demonstrated here that pretreatment of mice with the superantigens SEB and SPEA protected mice from lethal in- (37) . Further, we found that not only SEB but also rSPEA enhanced protection from L. monocytogenes infection and that CD8 ϩ T cells are the main effector for this host defense. We also provided new evidence that the enhanced protection of mice by pretreatment with SEB is due to an augmentative T-cell-mediated immune response rather than to an innate immune response. Moreover, we introduced new insight into the potential use of superantigens as adjuvantlike additives for new vaccine candidates.
Many exotoxins synthesized by S. aureus and S. pyogenes are now classified as superantigens. They were originally identified to cause food poisoning, fever, skin syndrome, or severe toxic shock syndrome (3, 18, 24) . Superantigens also stimulate large numbers of T cells and antigen-presenting cells (3) , which lead to greatly increased synthesis of inflammatory cytokines, e.g., IFN-␥, and enhanced innate immunity (10, 44, 49) and adaptive immunity (17, 56) after infection with intracellular parasites such as L. monocytogenes. Our study here clearly demonstrated that the administration of superantigen, either SEB or rSPEA, protected mice from lethal infection by L. monocytogenes (Fig. 1) . Furthermore, superantigen-primed protection of mice against lethal L. monocytogenes infection depends on the timing of the SEB administration, because pretreatment with SEB protected all mice from infection, whereas posttreatment with SEB did not ( Fig. 1 and data not shown) .
The host defense mechanism against primary L. monocytogenes infection in normal mice is due to the phagocytosis of TNF-␣-producing macrophages, which are activated by IFN-␥ produced by NK cells (10, 44, 49) . Resistance to secondary L. monocytogenes infection requires T cells (14) . However, since SCID mice and TCR ␤-chain-, MHC class I-, or class IIdeficient mice survived primary infection of L. monocytogenes (2, 21, 25) , T cells are not the main effector cells to protect the host from primary infection. In our study, pretreatment with SEB enhanced Listeria-specific T-cell responses but not innate immune responses (Fig. 3, 4 , 5, and 6). Furthermore, the protection of SEB-pretreated mice from primary L. monocytogenes infection was abolished by depletion of T cells but not by depletion of NK cells (Fig. 7) . These results indicate that SEB-primed protection mechanism is mainly due to T-celldependent adaptive immunity, which is different from that in normal mice.
Attempts were made to determine what types of protection mechanisms functioned in mice given SEB. SEB administration to mice enhanced Listeria-specific CD8 ϩ CTL activity, which in turn inhibited intracellular proliferation of this organism and protected the mice from the infection (Fig. 5, 6, and 8 ). This protection, however, was diminished after depletion of CTLs by injection of anti-CD4 antibodies ( Fig. 7 and 8) . The enhanced bacterium-specific CTL activity was induced by the treatment with SEB in in vitro model systems (30, 35) . However, in vivo augmentation of the CTL activity has not been demonstrated in relation to the protection from intracellular pathogens.
Yang et al. (56) indicated that endogenous IFN-␥, which is produced at the initial stage of the infection, actually plays a critical role in the generation of protective T cells against L. monocytogenes. These protective T cells produce IFN-␥, and the amount of IFN-␥ is correlated with the magnitude of the protection from L. monocytogenes infection (22, 29, 50, 51) . These results raised the question as to whether pretreatment with SEB enhanced IFN-␥ production and contributed to the enhanced protection. Our studies showed that secretion of IFN-␥ in SEB-primed mice increased temporarily (Fig. 2) . Although pretreatment with SEB increased the number of IFN-␥-producing CD8 ϩ CTL after L. monocytogenes infection FIG. 9 . Protection against L. monocytogenes challenge in HKL-immunized mice and effect of SEB. Groups of 10 mice were injected with SEB (10 g) or CFA (100 l) and immunized s.c. with HKL (5 ϫ 10 7 CFU) twice as indicated. These mice were infected with 10 4 CFU of L. monocytogenes/mouse 63 days after the initial immunization. Spleen was harvested 4 days after the infection, and the number of L. monocytogenes colonies in the spleen was determined. P ϭ 0.0095, 0.0065, 0.0020, 0.0057, and 0.0012 for group A compared to groups B to F, respectively. (Fig. 6) , the secretion of IFN-␥ in the sera of SEB-pretreated mice was diminished very promptly (Fig. 2) . These results suggested that IFN-␥ production just after SEB pretreatment might enhance the number of IFN-␥-producing CD8 ϩ CTLs, which contributes to the enhanced protection from L. monocytogenes infection. However, there still remains the question as to why SEB pretreatment decreased the secretion of IFN-␥ after the infection.
We have clearly shown that Listeria-specific CD4 ϩ T-cell activity was enhanced (Fig. 4) . The most important role of CD4 ϩ T cells in SEB-primed mice appeared to support the induction of CD8 ϩ CTLs, similar to the previous demonstration that the generation of CTLs requires help from CD4 ϩ T cells (1, 5, 23, 53) . Several investigators made trials to interpret the phenomenon by CD4 ϩ T-cell-CD8 ϩ T-cell collaborations (12, 23, 33, 43, 47) . In this model, CD4
ϩ T cells first stimulate macrophages to express costimulatory ligand, B7, so that they become competent to stimulate CD8 ϩ T cells. SEB might augment the reaction of this model, resulting in the enhanced CTL activity. However, this hypothesis has yet to be confirmed experimentally.
SEB priming increased the number of CD8 ϩ CTLs recognizing the peptides of LLO and murein hydrolase p60 protein (Fig. 6) . Not only L. monocytogenes but also other intracellular pathogens, i.e., Mycobacterium tuberculosis and Salmonella enterica serovar Enteritidis, have antigens that are recognized by CTLs (8, 26, 41) . Therefore, it is possible that enhanced protection in SEB-primed mice could be effective against several intracellular pathogens.
Pretreatment with SEB protected all mice from the infection, whereas posttreatment with SEB did not show the protection ( Fig. 1 and data not shown) . It is of interest that SEB exhibited marked adjuvant activity when mice were immunized with SEB and HKL. The adjuvant activity of SEB was significantly stronger than that of CFA under the condition used (Fig. 9) . Since there are few adjuvants which induce antigenspecific CTL activity, such as immunostimulatory complexes (36, 48) , SEB could be one of the rare adjuvants to enhance CTL activity.
Thus, pretreatment with sublethal doses of superantigens protects mice from lethal L. monocytogenes infection, which is most likely due to the increased number of L. monocytogenesspecific CD8
ϩ CTLs in the presence of CD4 ϩ T cells. Superantigens such as SEB may therefore be a useful tool in the protection of hosts from infections with intracellular pathogens, including L. monocytogenes.
